Prelude Therapeutics Analyst Ratings
Prelude Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/07/2023 | 68.92% | HC Wainwright & Co. | $6 → $5 | Maintains | Buy |
| 10/19/2023 | 102.7% | HC Wainwright & Co. | $17 → $6 | Maintains | Buy |
| 08/17/2023 | 474.32% | HC Wainwright & Co. | → $17 | Reiterates | Buy → Buy |
| 08/04/2023 | 237.84% | Morgan Stanley | $10 → $10 | Reiterates | Equal-Weight → Equal-Weight |
| 08/04/2023 | 68.92% | Barclays | $7 → $5 | Maintains | Equal-Weight |
| 03/17/2023 | 474.32% | HC Wainwright & Co. | $15 → $17 | Maintains | Buy |
| 11/21/2022 | 102.7% | B of A Securities | → $6 | Downgrades | Neutral → Underperform |
| 11/17/2022 | 406.76% | HC Wainwright & Co. | $16 → $15 | Maintains | Buy |
| 11/15/2022 | 237.84% | Morgan Stanley | $11 → $10 | Maintains | Equal-Weight |
| 09/09/2022 | 271.62% | Morgan Stanley | $19 → $11 | Downgrades | Overweight → Equal-Weight |
| 07/29/2022 | 204.05% | Jefferies | → $9 | Initiates Coverage On | → Buy |
| 05/12/2022 | 440.54% | HC Wainwright & Co. | $62 → $16 | Maintains | Buy |
| 03/17/2022 | 541.89% | Morgan Stanley | $20 → $19 | Maintains | Overweight |
| 03/15/2022 | 237.84% | B of A Securities | $50 → $10 | Downgrades | Buy → Neutral |
| 02/28/2022 | 305.41% | Barclays | $20 → $12 | Downgrades | Overweight → Equal-Weight |
| 11/17/2021 | 575.68% | Barclays | $33 → $20 | Maintains | Overweight |
| 10/11/2021 | 1082.43% | Morgan Stanley | $60 → $35 | Upgrades | Equal-Weight → Overweight |
| 10/08/2021 | 1014.86% | Barclays | $80 → $33 | Maintains | Overweight |
| 07/27/2021 | 1927.03% | B of A Securities | → $60 | Upgrades | Neutral → Buy |
| 04/26/2021 | 1994.59% | HC Wainwright & Co. | → $62 | Initiates Coverage On | → Buy |
| 03/17/2021 | 1927.03% | Morgan Stanley | $47 → $60 | Maintains | Equal-Weight |
| 12/16/2020 | 1487.84% | Morgan Stanley | $38 → $47 | Maintains | Equal-Weight |
| 11/12/2020 | 1183.78% | Morgan Stanley | $34 → $38 | Maintains | Equal-Weight |
| 10/20/2020 | 1251.35% | B of A Securities | → $40 | Initiates Coverage On | → Buy |
| 10/20/2020 | 1150% | Goldman Sachs | → $37 | Initiates Coverage On | → Neutral |
| 10/20/2020 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/07/2023 | 68.92% | HC Wainwright & Co. | 6 美元 → 5 美元 | 维护 | 买 |
| 2023 年 10 月 19 日 | 102.7% | HC Wainwright & Co. | 17 美元 → 6 美元 | 维护 | 买 |
| 08/17/2023 | 474.32% | HC Wainwright & Co. | → 17 美元 | 重申 | 购买 → 购买 |
| 08/04/2023 | 237.84% | 摩根士丹利 | 10 美元 → 10 美元 | 重申 | 等重 → 等重 |
| 08/04/2023 | 68.92% | 巴克莱 | 7 美元 → 5 美元 | 维护 | 重量相等 |
| 03/17/2023 | 474.32% | HC Wainwright & Co. | 15 美元 → 17 美元 | 维护 | 买 |
| 11/21/2022 | 102.7% | B of A 类证券 | → 6 美元 | 降级 | 中性 → 跑赢大盘 |
| 11/17/2022 | 406.76% | HC Wainwright & Co. | 16 美元 → 15 美元 | 维护 | 买 |
| 11/15/2022 | 237.84% | 摩根士丹利 | 11 美元 → 10 美元 | 维护 | 重量相等 |
| 09/09/2022 | 271.62% | 摩根士丹利 | 19 美元 → 11 美元 | 降级 | 超重 → 重量相等 |
| 07/29/2022 | 204.05% | 杰富瑞集团 | → 9 美元 | 启动覆盖范围开启 | → 购买 |
| 05/12/2022 | 440.54% | HC Wainwright & Co. | 62 美元 → 16 美元 | 维护 | 买 |
| 03/17/2022 | 541.89% | 摩根士丹利 | 20 美元 → 19 美元 | 维护 | 超重 |
| 2022 年 3 月 15 日 | 237.84% | B of A 类证券 | 50 美元 → 10 美元 | 降级 | 买入 → 中性 |
| 02/28/2022 | 305.41% | 巴克莱 | 20 美元 → 12 美元 | 降级 | 超重 → 重量相等 |
| 11/17/2021 | 575.68% | 巴克莱 | 33 美元 → 20 美元 | 维护 | 超重 |
| 2021 年 11 月 10 日 | 1082.43% | 摩根士丹利 | 60 美元 → 35 美元 | 升级 | 重量相等 → 超重 |
| 2021 年 8 月 10 日 | 1014.86% | 巴克莱 | 80 美元 → 33 美元 | 维护 | 超重 |
| 2021 年 7 月 27 日 | 1927.03% | B of A 类证券 | → 60 美元 | 升级 | 中性 → 买入 |
| 04/26/2021 | 1994.59% | HC Wainwright & Co. | → 62 美元 | 启动覆盖范围开启 | → 购买 |
| 03/17/2021 | 1927.03% | 摩根士丹利 | 47 美元 → 60 美元 | 维护 | 重量相等 |
| 2020 年 12 月 16 日 | 1487.84% | 摩根士丹利 | 38 美元 → 47 美元 | 维护 | 重量相等 |
| 11/12/2020 | 1183.78% | 摩根士丹利 | 34 美元 → 38 美元 | 维护 | 重量相等 |
| 10/20/2020 | 1251.35% | B of A 类证券 | → 40 美元 | 启动覆盖范围开启 | → 购买 |
| 10/20/2020 | 1150% | 高盛 | → 37 美元 | 启动覆盖范围开启 | → 中立 |
| 10/20/2020 | — | 摩根士丹利 | 启动覆盖范围开启 | → 重量相等 |
What is the target price for Prelude Therapeutics (PRLD)?
Prelude Therapeutics（PRLD）的目标价格是多少？
The latest price target for Prelude Therapeutics (NASDAQ: PRLD) was reported by HC Wainwright & Co. on November 7, 2023. The analyst firm set a price target for $5.00 expecting PRLD to rise to within 12 months (a possible 68.92% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月7日公布了Prelude Therapeutics（纳斯达克股票代码：PRLD）的最新目标股价。该分析公司将目标股价定为5.00美元，预计PRLD将在12个月内升至12个月内（可能上涨68.92％）。去年有9家分析公司公布了评级。
What is the most recent analyst rating for Prelude Therapeutics (PRLD)?
分析师对Prelude Therapeutics（PRLD）的最新评级是多少？
The latest analyst rating for Prelude Therapeutics (NASDAQ: PRLD) was provided by HC Wainwright & Co., and Prelude Therapeutics maintained their buy rating.
Prelude Therapeutics（纳斯达克股票代码：PRLD）的最新分析师评级由HC Wainwright & Co. 提供，Prelude Therapeutics维持买入评级。
When is the next analyst rating going to be posted or updated for Prelude Therapeutics (PRLD)?
Prelude Therapeutics（PRLD）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prelude Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prelude Therapeutics was filed on November 7, 2023 so you should expect the next rating to be made available sometime around November 7, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Prelude Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Prelude Therapeutics的最新评级是在2023年11月7日公布的，因此您应该预计下一个评级将在2024年11月7日左右公布。
Is the Analyst Rating Prelude Therapeutics (PRLD) correct?
分析师评级 Prelude Therapeutics (PRLD) 正确吗？
While ratings are subjective and will change, the latest Prelude Therapeutics (PRLD) rating was a maintained with a price target of $6.00 to $5.00. The current price Prelude Therapeutics (PRLD) is trading at is $2.96, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Prelude Therapeutics（PRLD）评级保持不变，目标股价为6.00美元至5.00美元。Prelude Therapeutics（PRLD）目前的交易价格为2.96美元，超出了分析师的预期区间。